Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 3/2011

01-06-2011 | Editorial

miR-200c at the nexus of epithelial-mesenchymal transition, resistance to apoptosis, and the breast cancer stem cell phenotype

Author: Derek C Radisky

Published in: Breast Cancer Research | Issue 3/2011

Login to get access

Abstract

Decreased expression of miRNAs of the miR-200 family has been implicated in the growth and metastasis of breast cancer cells. Of this family, miR-200c has garnered particular attention as a consequence of its ability to target ZEB1 and ZEB2, mediators of epithelial- mesenchymal transition. An article in the previous issue of Breast Cancer Research identifies additional targets of miR-200c that link increased cancer cell invasiveness, resistance to apoptosis, and induction of breast cancer stem cell characteristics.
Literature
1.
Howe EN, Cochrane DR, Richer JK: Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res. 2011, 13: R45-10.1186/bcr2867.CrossRefPubMedPubMedCentral
2.
3.
Brabletz S, Brabletz T: The ZEB/miR-200 feedback loop - a motor of cellular plasticity in development and cancer?. EMBO Rep. 2010, 11: 670-677. 10.1038/embor.2010.117.CrossRefPubMedPubMedCentral
4.
Wright JA, Richer JK, Goodall GJ: MicroRNAs and EMT in mammary cells and breast cancer. J Mammary Gland Biol Neoplasia. 2010, 15: 213-223. 10.1007/s10911-010-9183-z.CrossRefPubMed
5.
6.
Cochrane DR, Howe EN, Spoelstra NS, Richer JK: Loss of miR-200c: a marker of aggressiveness and chemoresistance in female reproductive cancers. J Oncol. 2010, 2010: 821717-CrossRefPubMed
7.
Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK: MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther. 2009, 8: 1055-1066.CrossRefPubMedPubMedCentral
8.
Chiarugi P, Giannoni E: Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol. 2008, 76: 1352-1364. 10.1016/j.bcp.2008.07.023.CrossRefPubMed
9.
Smit MA, Peeper DS: Zeb1 is required for TrkB-induced epithelial- mesenchymal transition, anoikis resistance and metastasis. Oncogene. 2011, 10.1038/onc.2011.96. [Epub ahead of print]
10.
Schickel R, Park SM, Murmann AE, Peter ME: miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell. 2010, 38: 908-915. 10.1016/j.molcel.2010.05.018.CrossRefPubMedPubMedCentral
11.
Reiman JM, Knutson KL, Radisky DC: Immune promotion of epithelial- mesenchymal transition and generation of breast cancer stem cells. Cancer Res. 2010, 70: 3005-3008. 10.1158/0008-5472.CAN-09-4041.CrossRefPubMedPubMedCentral
12.
Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, Pera RA, Lao K, Clarke MF: Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009, 138: 592-603. 10.1016/j.cell.2009.07.011.CrossRefPubMedPubMedCentral
13.
Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K: Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell. 2010, 39: 761-772. 10.1016/j.molcel.2010.08.013.CrossRefPubMedPubMedCentral
14.
Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T: The EMT-activator ZEB1 promotes tumorigenicity by repressing stemnessinhibiting microRNAs. Nat Cell Biol. 2009, 11: 1487-1495. 10.1038/ncb1998.CrossRefPubMed
15.
Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009, 69: 1302-1313. 10.1158/0008-5472.CAN-08-2741.CrossRefPubMedPubMedCentral
Metadata
Title
miR-200c at the nexus of epithelial-mesenchymal transition, resistance to apoptosis, and the breast cancer stem cell phenotype
Author
Derek C Radisky
Publication date
01-06-2011
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 3/2011
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2885

Other articles of this Issue 3/2011

Breast Cancer Research 3/2011 Go to the issue

Research article

Coffee consumption modifies risk of estrogen-receptor negative breast cancer

Research article

Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism

Research article

Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer

Research article

Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

Editorial

Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4

Research article

The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits